February 27, 2025
A Maryland federal judge approved a $40 million settlement between Emergent BioSolutions Inc. and a class of investors claiming that it misled them about its ability to meet the demands of two high-profile contracts to produce components of COVID-19 vaccines, leading the stock price to tumble after production deficiencies were discovered.
September 13, 2024
Emergent BioSolutions has agreed to pay $40 million to settle a consolidated class action alleging it misled investors about how prepared it was to handle two high-profile deals to manufacture COVID-19 vaccines.
September 05, 2023
A Maryland federal judge trimmed a consolidated class action claiming that Emergent BioSolutions Inc. misled investors about how prepared it was to handle two high-profile deals to manufacture COVID-19 vaccines, ruling that the investors' fraud claims relating to past earning statements and internal controls can be dismissed.
June 21, 2021
Entwistle & Cappucci LLP and Wolf Haldenstein Adler Freeman & Herz LLP are competing in Maryland federal court to represent a proposed class of investors in a consolidated action claiming that biopharmaceutical company Emergent BioSolutions Inc. misled the public about how prepared it was to handle a pair of high-profile deals to manufacture COVID-19 vaccines.